NASDAQ:FBIO - Fortress Biotech Stock Price, Forecast & News

Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO."

Fortress Biotech (NASDAQ:FBIO) announced its earnings results on Friday, August, 9th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping the Zacks' consensus estimate of ($0.46) by $0.22. The biopharmaceutical company earned $9.25 million during the quarter, compared to the consensus estimate of $7.51 million. Fortress Biotech had a negative net margin of 143.08% and a negative return on equity of 131.74%. View Fortress Biotech's Earnings History.

Fortress Biotech is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Fortress Biotech.

5 equities research analysts have issued 1-year target prices for Fortress Biotech's stock. Their forecasts range from $4.00 to $19.00. On average, they anticipate Fortress Biotech's share price to reach $9.80 in the next year. This suggests a possible upside of 240.3% from the stock's current price. View Analyst Price Targets for Fortress Biotech.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fortress Biotech.

Headlines about FBIO stock have been trending extremely negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Fortress Biotech earned a news impact score of -5.0 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Fortress Biotech.

Fortress Biotech saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 1,090,000 shares, an increase of 64.2% from the December 31st total of 664,000 shares. Based on an average daily trading volume, of 328,600 shares, the short-interest ratio is presently 3.3 days. Approximately 2.2% of the shares of the stock are sold short. View Fortress Biotech's Current Options Chain.

Some companies that are related to Fortress Biotech include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Fortress Biotech investors own include TG Therapeutics (TGTX), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Agile Therapeutics (AGRX), Geron (GERN), Advanced Micro Devices (AMD), Vaxart (VXRT), Protalix Biotherapeutics (PLX), Aduro BioTech (ADRO) and Anavex Life Sciences (AVXL).

Fortress Biotech's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Cpwm LLC (0.57%), Renaissance Technologies LLC (0.52%), Shikiar Asset Management Inc. (0.44%), Oxford Asset Management LLP (0.35%), Credit Suisse AG (0.16%) and Bank of New York Mellon Corp (0.12%). Company insiders that own Fortress Biotech stock include George Avgerinos and Robyn Hunter. View Institutional Ownership Trends for Fortress Biotech.

FBIO stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP and State Street Corp. View Insider Buying and Selling for Fortress Biotech.

FBIO stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Oxford Asset Management LLP, Shikiar Asset Management Inc., Credit Suisse AG, Bank of New York Mellon Corp, Goldman Sachs Group Inc., Banco Bilbao Vizcaya Argentaria S.A. and Alpine Global Management LLC. View Insider Buying and Selling for Fortress Biotech.

Shares of FBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of FBIO stock can currently be purchased for approximately $2.88.

Fortress Biotech has a market capitalization of $203.85 million and generates $26.88 million in revenue each year. The biopharmaceutical company earns $-84,150,000.00 in net income (profit) each year or ($3.01) on an earnings per share basis. Fortress Biotech employs 68 workers across the globe.View Additional Information About Fortress Biotech.

The official website for Fortress Biotech is http://www.fortressbiotech.com/.

Fortress Biotech's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 781-652-4500 or via email at [email protected]